



NEWS RELEASE

LITHOGOLD® STUDY SUBMITTED TO FDA

July 21, 2006 (Woodstock, Georgia) – Tissue Regeneration Technologies, LLC (TRT) announced that today it submitted the study data for its LithoGold® lithotripsy system under an FDA 510(k) clinical trial. The LithoGold electrohydraulic ESWL system was used according to the clinical study protocol to treat 20 subjects with renal or ureteral calculi. Two investigational sites participated in the study; one site in Norwalk, Ohio enrolled 4 subjects and one site in Bellevue, Ohio enrolled 16 subjects. The 20 subjects presented with a total of 22 calculi for treatment, 16 of which were in the kidney and 6 of which were in the ureter (lower – 3, middle – 1, upper – 2). All LithoGold study procedures were performed according to the study protocol, and all 20 subjects completed the requirements of the study protocol.

At the 7-day follow up visit, 19 of the 20 subjects met the individual success criterion for the study: no subject retained stone fragments greater than 4mm in size, but one subject required a basket extraction of a 3mm stone fragment. *Therefore, the overall study success rate was 95%.*

The LithoGold utilizes exclusive patented technology to ensure more consistent shockwaves than any other lithotripsy device. It also offers the largest treatment area and deepest penetration depth of any lithotripter on the market and is modular, transportable and highly versatile. “Our LithoGold was aptly named because it sets the new Gold Standard in kidney and ureter stone treatment,” stated John Warlick, TRT President. “We hope to have approval to market this device in the United States within 90 days.”

About Tissue Regeneration Technologies

Tissue Regeneration Technologies is a leading-edge health care company that believes in “doing well by doing good.” Its state-of-the-art medical devices utilize MultiWaves™ (Pulsed Acoustic Wave technology) for non-invasive treatment of chronically infected wounds, periodontal indications, ischemic heart disease and orthopedic indications such as tendinopathies, osteoarthritis and avascular conditions of the bones. TRT is headquartered in and operates its urology division, Shockwave Technical Service (STS), from Woodstock, Georgia. STS provides technical service, repair and maintenance for medical devices. Medical device production is handled by TRT’s manufacturing subsidiary, MTS Europe GmbH, located in Konstanz, Germany. TRT’s devices are currently distributed in approximately 20 countries throughout North America, Europe, Asia, Africa and South America. For more information, please visit the company’s website at www.trtllc.com.

Contact information: Tissue Regeneration Technologies, Julie Dodd, (770) 966-1315 or jdodd@trtllc.com